4.1 Article

Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization

期刊

INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 104, 期 3, 页码 344-357

出版社

SPRINGER JAPAN KK
DOI: 10.1007/s12185-016-2043-x

关键词

Macrocytic anemia; MCV; Bone marrow failure syndromes; Megaloblastic anemia; Solid tumors

资金

  1. Tohoku Hematology Forum (THF), Tohoku Hematology Expert Meeting (NPO-THEMe)
  2. Grants-in-Aid for Scientific Research [16K09854] Funding Source: KAKEN

向作者/读者索取更多资源

There have been no studies on the distribution of causes of macrocytic anemia with respect to mean corpuscular volume (MCV) cutoff values. We retrospectively investigated the causes of macrocytic anemia (MCV aeyen100 fL) among 628 patients who visited the outpatient hematology clinic in Tohoku University Hospital. To ensure data validity, we also analyzed data from 307 patients in eight other hospitals in the Tohoku district. The leading causes of macrocytic anemia (number of patients, %) were myelodysplastic syndromes (121, 19.3 %), suspected bone marrow failure syndromes (BMF; 74, 11.8 %), aplastic anemia (51, 8.1 %), plasma cell dyscrasia (45, 7.2 %), and vitamin B12 deficiency (40, 6.4 %) in Tohoku University Hospital. We made three primary findings as follows. First, the most common cause of macrocytic anemia is BMF. Second, lymphoid and solid malignancies are also common causes of macrocytosis. Third, macrocytic anemia may be classified into three groups: Group 1 (megaloblastic anemia and medications), which can exceed MCV 130 fL; Group 2 (alcoholism/liver disease, BMF, myeloid malignancy, and hemolytic anemia), which can exceed MCV 114 fL; and Group 3 (lymphoid malignancy, chronic renal failure, hypothyroidism, and solid tumors), which does not exceed MCV 114 fL. These conclusions were supported by the results from eight other hospitals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Hematology

Sustained remission of giant pancreatic plasmacytoma with daratumumab

Satoshi Ichikawa, Eijiro Furukawa, Kei Saito, Noriko Fukuhara, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

ANNALS OF HEMATOLOGY (2021)

Letter Hematology

A novel case of γδ T cell leukemia with recurrent genetic abnormalities accompanied by agranulocytosis

Satoshi Ichikawa, Tohru Fujiwara, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Shunsuke Hatta, Koichi Onodera, Yasushi Onishi, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

ANNALS OF HEMATOLOGY (2021)

Article Biophysics

Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors

Satoko Morishima, Takahiro Fukuda, Noriko Doki, Takehiko Mori, Makoto Onizuka, Toshihiro Kawakita, Chiaki Kato, Yukiyasu Ozawa, Masatsugu Tanaka, Mineo Kurokawa, Tomohiko Kamimura, Masami Inoue, Junji Tanaka, Tatsuo Ichinohe, Yoshiko Atsuta, Yasuo Morishima

Summary: This study found that specific HLAs, such as HLA-B60 and HLA-B62, are significantly associated with the risk of acute GVHD in patients undergoing allo-HSCT. HLA-B62-positive patients have a higher risk of leukemia relapse, while overall survival is not affected by these specific HLAs. The findings suggest that consideration of specific HLAs may help predict transplant outcomes.

BONE MARROW TRANSPLANTATION (2021)

Article Biophysics

Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation

Hisayuki Yokoyama, Junya Kanda, Yuta Kawahara, Naoyuki Uchida, Masatsugu Tanaka, Satoshi Takahashi, Makoto Onizuka, Yuma Noguchi, Yukiyasu Ozawa, Yuna Katsuoka, Shuichi Ota, Takanori Ohta, Takafumi Kimura, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Hideki Nakasone, Satoko Morishima

Summary: The study revealed that in cord blood transplantation patients, CMV reactivation has a protective effect against disease relapse when there is a KIR3DL-ligand mismatch.

BONE MARROW TRANSPLANTATION (2021)

Article Infectious Diseases

Second direct-acting antiviral therapy for hepatitis C virus infection after umbilical cord blood transplantation: A case report

Koichi Onodera, Yasushi Onishi, Jun Inoue, Yuya Tanaka, Lee Yonha, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Kazunori Murai, Atsushi Masamune, Hideo Harigae

Summary: This article reports the clinical course of a umbilical cord blood recipient treated with direct-acting antivirals for HCV infection before transplantation. Confirming sustained virological response before transplantation is crucial but often challenging. Further investigation is needed to clarify the optimal management of HCV infection for allogeneic HSCT recipients in the DAA era.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2021)

Letter Hematology

T-cell receptor-silent peripheral T-cell lymphoma complicated with hemophagocytic lymphohystiocytosis

Koya Ono, Yasushi Onishi, Koichi Onodera, Daigo Michimata, Eijiro Furukawa, Kazuki Sakurai, Naoya Morota, Takumi Sawada, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Hirofumi Watanabe, Chie Suzuki, Hideo Harigae

ANNALS OF HEMATOLOGY (2022)

Article Medicine, General & Internal

Salvage Cord Blood Transplantation for Sustained Remission of Acute Megakaryoblastic Leukemia That Relapsed Early after Myeloablative Transplantation

Satoshi Ichikawa, Tohru Fujiwara, Kei Saito, Kazuki Sakurai, Kyoko Inokura, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Yasushi Onishi, Junichi Kameoka, Hideo Harigae

Summary: This case report discusses a patient with acute megakaryoblastic leukemia, who had previously developed a mediastinal germ cell tumor and relapsed early after allogeneic hematopoietic stem cell transplantation. However, successful treatment was achieved through salvage cord blood transplantation with reduced-intensity conditioning, leading to sustained remission and a favorable general condition. The graft-versus-leukemia effect of CBT may hold promise for refractory AMKL therapy.

INTERNAL MEDICINE (2021)

Article Oncology

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Naoko Hosono, Hisayuki Yokoyama, Nobuyuki Aotsuka, Kiyoshi Ando, Hiroatsu Iida, Takayuki Ishikawa, Kensuke Usuki, Masahiro Onozawa, Masahiro Kizaki, Kohmei Kubo, Junya Kuroda, Yukio Kobayashi, Takayuki Shimizu, Shigeru Chiba, Miho Nara, Tomoko Hata, Michihiro Hidaka, Shin-Ichiro Fujiwara, Yoshinobu Maeda, Yasuyoshi Morita, Mikiko Kusano, Qiaoyang Lu, Shuichi Miyawaki, Erhan Berrak, Nahla Hasabou, Tomoki Naoe

Summary: The FLT3 inhibitor gilteritinib has shown superior overall survival in Japanese patients with FLT3(mut+) R/R AML compared to salvage chemotherapy, with fewer adverse events in the gilteritinib group after adjustment for drug exposure.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Hematology

Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

Isamu Sugiura, Noriko Doki, Tomoko Hata, Ryuko Cho, Toshiro Ito, Youko Suehiro, Masatsugu Tanaka, Shinichi Kako, Mitsuhiro Matsuda, Hisayuki Yokoyama, Yuichi Ishikawa, Yasuhiro Taniguchi, Maki Hagihara, Yukiyasu Ozawa, Yasunori Ueda, Daiki Hirano, Toru Sakura, Masaaki Tsuji, Tsuyoshi Kamae, Hiroyuki Fujita, Nobuhiro Hiramoto, Masahiro Onoda, Shin Fujisawa, Yoshihiro Hatta, Nobuaki Dobashi, Satoshi Nishiwaki, Yoshiko Atsuta, Yukio Kobayashi, Fumihiko Hayakawa, Shigeki Ohtake, Tomoki Naoe, Yasushi Miyazaki

Summary: This study evaluated the use of dasatinib-based 2-step induction in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The results showed that this treatment approach significantly improved the 3-year event-free survival rate in these patients.

BLOOD ADVANCES (2022)

Article Biophysics

Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation

Hisayuki Yokoyama, Masahiro Hirayama, Yoshiyuki Takahashi, Naoyuki Uchida, Masatsugu Tanaka, Makoto Onizuka, Yukiyasu Ozawa, Daishi Onai, Yuna Katsuoka, Atsushi Wake, Masashi Sawa, Hikaru Kobayashi, Yumiko Maruyama, Kazutaka Ozeki, Takafumi Kimura, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Seitaro Terakura, Satoko Morishima

Summary: The effects of KIR-ligand mismatch in CBT recipients vary depending on the type of GVHD prophylaxis, with mismatch exacerbating non-relapse mortality and impacting overall survival in the MMF group. HLA-C2 mismatch showed favorable effects in reducing relapse incidence and improving OS in the MTX group, while HLA-A3/A11 mismatch in the MMF group worsened NRM and OS. These findings highlight the importance of assessing KIR-ligand mismatch status in CBT patients.

BONE MARROW TRANSPLANTATION (2021)

Article Oncology

Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia

Yoshimitsu Shimomura, Tomotaka Sobue, Shigeki Hirabayashi, Tadakazu Kondo, Shohei Mizuno, Junya Kanda, Takahiro Fujino, Keisuke Kataoka, Naoyuki Uchida, Tetsuya Eto, Shigesaburo Miyakoshi, Masatsugu Tanaka, Toshiro Kawakita, Hisayuki Yokoyama, Noriko Doki, Kaito Harada, Atsushi Wake, Shuichi Ota, Satoru Takada, Satoshi Takahashi, Takafumi Kimura, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Masamitsu Yanada

Summary: CBT transplantation resulted in better 5-year progression-free survival compared to MRDT in patients with non-remission R/R AML, mainly due to a lower relapse rate and a higher non-relapse mortality rate in the CBT group.

LEUKEMIA (2022)

Article Biophysics

Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch

Hisayuki Yokoyama, Minoru Kanaya, Tomoki Iemura, Masahiro Hirayama, Satoshi Yamasaki, Tadakazu Kondo, Naoyuki Uchida, Satoshi Takahashi, Masatsugu Tanaka, Makoto Onizuka, Yukiyasu Ozawa, Yasuji Kozai, Tetsuya Eto, Yasuhiro Sugio, Atsushi Hamamura, Toshiro Kawakita, Nobuyuki Aotsuka, Satoru Takada, Atsushi Wake, Takafumi Kimura, Tatsuo Ichinohe, Yoshiko Atsuta, Masamitsu Yanada, Satoko Morishima

Summary: KIR-ligand mismatch may have a positive impact on cord blood transplantation outcomes in acute myeloid leukemia (AML) patients, particularly when using calcineurin inhibitor plus methotrexate (CNI/MTX) for graft-versus-host disease (GVHD) prophylaxis. However, this effect was not observed in patients with other KIR-ligand mismatch types or those using CNI/mofetil (MMF) for GVHD prophylaxis.

BONE MARROW TRANSPLANTATION (2022)

Article Hematology

Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders

Yasushi Onishi, Koichi Onodera, Noriko Fukuhara, Hiroki Kato, Satoshi Ichikawa, Tohru Fujiwara, Hisayuki Yokoyama, Minami Yamada-Fujiwara, Hideo Harigae

Summary: Unrelated cord blood transplantation (UCBT) may be a promising treatment option for adult-onset EBV-T/NK-LPDs, but for CAEBV patients, there is a higher risk of graft failure.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)

Article Mathematical & Computational Biology

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response

Yuji Okamoto, Mitsuhito Hirano, Kai Morino, Masashi K. Kajita, Shinji Nakaoka, Mayuko Tsuda, Kei-ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Hisashi Wakita, Kaichi Nishiwaki, Arinobu Tojo, Kazuyuki Aihara

Summary: This study successfully classified CML patients with different nilotinib responses by using a dynamical model and laboratory findings. A method was proposed to identify patients who failed to achieve a treatment goal based on data collected at three initial time points only.

NPJ SYSTEMS BIOLOGY AND APPLICATIONS (2022)

Article Hematology

Aleukemic T-Iymphoblastic leukemia/lymphoma with massive cerebrospinal fluid infiltration

Satoshi Ichikawa, Noriko Fukuhara, Tsuyoshi Doman, Daichi Kiba, Yuya Tanaka, Kyoko Inokura, Naoya Morota, Koya Ono, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

Summary: This case report presents a rare presentation of T-lymphoblastic leukemia/lymphoma (T-ALL/LBL), where the patient initially showed only central nervous system infiltration without leukemic symptoms. It emphasizes the importance of recognizing this exceptional presentation to avoid delayed diagnosis and treatment.

JOURNAL OF HEMATOPATHOLOGY (2022)

暂无数据